Daxing Biopharmaceutical Base in Zhongguancun National Innovation Demonstration Zone has thrived in development, achieving a record total output value of industrial enterprises above the designated scale. As of May, 66 enterprises above the designated size in the base registered a total industrial output value of 61.95 billion yuan, total tax payments of 3.46 billion yuan and a total investment of 1.99 billion yuan in fixed assets, contributing the power of the pharmaceutical industry to Beijing's economic development.
Top domestic and foreign enterprises have flocked in. Daxing Biopharmaceutical Base has brought together national drug administration, test and R&D institutions such as National Institutes for Food and Drug Control and Chinese Academy of Medical Science, and attracted Fresenius Kabi among Fortune Global 500, as well as a number of domestic and foreign top enterprises with world leading technologies like Sinovac, Minhai Biotechnology and Hotgen. It has become an important support area for the development of China's high-end medical and health industry and technology innovation.
An important period of historical development has come to the biopharmaceutical base as the biopharmaceutical industry has become a leading industry in Daxing and the construction of the "two zones" has become a major central policy supporting the opening-up and development of Beijing To attract more biopharmaceutical enterprises to the park, Daxing Biopharmaceutical Base has started to expand. Inspired by the idea of clustered development, the base will create a space of nearly 30 square kilometers for industrial development, intensify support for the construction of innovation and startup incubators, open laboratories, pilot scale production lines and other service platforms, and build up a number of professional industrial incubation platforms. (Source: Beijing Daily)